Literature DB >> 7376124

Severe asthma after inadvertent ingestion of oxprenolol.

I P Williams, F J Millard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7376124      PMCID： PMC471246          DOI： 10.1136/thx.35.2.160

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  1 in total

Review 1.  The clinical pharmacology of beta adrenergic blocking drugs.

Authors:  D G McDevitt; R G Shanks; B N Prichard
Journal:  J R Coll Physicians Lond       Date:  1976-10
  1 in total
  8 in total

1.  Effects of hydrocortisone on acute β-adrenoceptor blocker and histamine induced bronchoconstriction.

Authors:  Philip M Short; Peter A Williamson; Brian J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2012-05       Impact factor: 4.335

2.  Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane.

Authors:  J M Raine; M G Palazzo; J H Kerr; P Sleight
Journal:  Br Med J (Clin Res Ed)       Date:  1981-02-14

3.  Clinical trials in asthma.

Authors:  J Rees
Journal:  Br Med J (Clin Res Ed)       Date:  1983-08-06

4.  Respiratory function in the elderly and the effects of beta blockade.

Authors:  A E Tattersfield
Journal:  Cardiovasc Drugs Ther       Date:  1991-01       Impact factor: 3.727

5.  Plasma histamine concentration during propranolol induced bronchoconstriction.

Authors:  P W Ind; P J Barnes; M J Brown; C T Dollery
Journal:  Thorax       Date:  1985-12       Impact factor: 9.139

6.  Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study.

Authors:  Philip M Short; Samuel I W Lipworth; Douglas H J Elder; Stuart Schembri; Brian J Lipworth
Journal:  BMJ       Date:  2011-05-10

7.  Myocardial infarction during asthmatic attack induced by ingestion of propranolol.

Authors:  A B Millar
Journal:  J R Soc Med       Date:  1982-08       Impact factor: 18.000

8.  Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease.

Authors:  Jillian G Baker; Sheila M Gardiner; Jeanette Woolard; Christophe Fromont; Gopal P Jadhav; Shailesh N Mistry; Kevin S J Thompson; Barrie Kellam; Stephen J Hill; Peter M Fischer
Journal:  FASEB J       Date:  2017-04-11       Impact factor: 5.191
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.